Evidence map›Paper›PMID 32110111›Full record

ArticleClinical epidemiology2020

Use of Antidepressants and Risk of Cutaneous Melanoma: A Prospective Registry-Based Case-Control Study.

Leon Alexander Mclaren Berge, Bettina Kulle Andreassen, Jo S Stenehjem, Trond Heir, Kari Furu, Asta Juzeniene, Ingrid Roscher, Inger Kristin Larsen, Adele C Green, Marit B Veierød and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical epidemiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Repurposing autophagy regulators in brain tumors.International journal of cancer · 2022
    Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Leon Alexander Mclaren BergeDepartment of Research, Cancer Registry of Norway, Oslo, Norway.
Bettina Kulle AndreassenDepartment of Research, Cancer Registry of Norway, Oslo, Norway.
Jo S StenehjemDepartment of Research, Cancer Registry of Norway, Oslo, Norway.ORCID 0000-0002-1964-5410
Trond HeirInstitute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Kari FuruDepartment of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway.ORCID 0000-0003-2245-0179
Asta JuzenieneDepartment of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Ingrid RoscherDepartment of Rheumatology, Dermatology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.
Inger Kristin LarsenDepartment of Registration, Cancer Registry of Norway, Oslo, Norway.
Adele C GreenQIMR Berghofer Medical Research Institute, Brisbane, Australia.ORCID 0000-0002-2753-4841
Marit B VeierødOslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.ORCID 0000-0002-2083-2758
Trude E RobsahmDepartment of Research, Cancer Registry of Norway, Oslo, Norway.ORCID 0000-0002-1652-7734
Oslo University Hospital · NOCancer Registry of Norway · NOUniversity of Oslo · NONorwegian Institute of Public Health · NOQIMR Berghofer Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMelanoma is the cancer with the most rapidly rising incidence rate in Norway. Although exposure to ultraviolet radiation (UVR) is the major environmental risk factor, other factors may also contribute. Antidepressants have cancer inhibiting and promoting side effects, and their prescription rates have increased in parallel with melanoma incidence. Thus, we aimed to prospectively examine the association between use of antidepressants and melanoma by using nation-wide data from the Cancer Registry of Norway, the National Registry, the Norwegian Prescription Database and the Medical Birth Registry of Norway. PATIENT AND

methodsAll cases aged 18-85 with a primary cutaneous invasive melanoma diagnosed during 2007-2015 (n=12,099) were matched to population controls 1:10 (n=118,467) by sex and year of birth using risk-set sampling. We obtained information on prescribed antidepressants and other potentially confounding drug use (2004-2015). Conditional logistic regression was used to estimate adjusted rate ratios (RRs) and 95% confidence intervals (CIs) for the association between overall and class-specific use of antidepressants and incident melanoma.

resultsCompared with ≤1 prescription, ≥8 prescriptions of antidepressants overall were negatively associated with melanoma (RR 0.81 CI 0.75-0.87). Class-specific analyses showed decreased RRs for selective serotonin reuptake inhibitors (RR 0.82 CI 0.73-0.93) and mixed antidepressants (RR 0.77 CI 0.69-0.86). The negative association was found for both sexes, age ≥50 years, residential regions with medium and highest ambient UVR exposure, all histological subtypes, trunk, upper and lower limb sites and local disease.

conclusionUse of antidepressants was associated with decreased risk of melanoma. There are at least two possible explanations for our results; cancer-inhibiting actions induced by the drug and less UVR exposure among the most frequent users of antidepressants.

Indexed as

antidepressantsmelanomapharmacoepidemiologyprescription drugsregistry-based

Identifiers

PMID32110111
PMCPMC7042562
OpenAlexW3008429258

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.